分组1 - The company, Aquestive Therapeutics, is advancing medicines to improve patients' lives through innovative science and delivery technologies [2] - It operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [2] - The company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents [2] 分组2 - The company is advancing Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions, including anaphylaxis [2] - AQST-108 (epinephrine prodrug) topical gel is being developed for various dermatological conditions, including alopecia areata [2] - The AdrenaVerse™ platform contains a library of over 20 epinephrine prodrugs for potential allergy and dermatological indications [2] 分组3 - Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units and 50,000 non-qualified common stock options under the 2022 Equity Inducement Plan [1] - The equity awards will vest 25% after each of the first and second anniversaries of the grant date, and 50% on the third anniversary [1] - The awards were approved by the independent Compensation Committee as a material inducement for Dr. Greenhawt's acceptance of employment [1]

Core Insights - Madrigal Pharmaceuticals, Inc. has granted an equity award to Rita Thakkar, the new Chief Accounting Officer, as part of its 2025 Inducement Plan [1][2] - The equity award includes 2,398 time-based restricted stock units and options to purchase 1,826 shares of common stock, with an exercise price of $495.88 per share [2] - Madrigal focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its medication Rezdiffra being the first approved treatment for MASH with moderate to advanced fibrosis [3] Group 1 - The equity award was approved by Madrigal's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) [1] - Options vesting schedule includes 25% on the first anniversary and 6.25% quarterly thereafter, while restricted stock units vest in four equal installments over four years [2] - Rezdiffra is a once-daily, oral, liver-directed THR-β agonist targeting key causes of MASH, with ongoing trials for compensated MASH cirrhosis [3]